Assessing the safety and effectiveness of deucravacitinib for psoriasis in Japan
Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan
This study is testing how safe and effective the medication deucravacitinib is for people in Japan who have plaque psoriasis and are using it for the first time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | Deucravacitinib |
| Locations | 1 site (Tosima-ku, Tokyo) |
| Trial ID | NCT05633264 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety and effectiveness of deucravacitinib in participants with plaque psoriasis in Japan. Participants will be those who are receiving deucravacitinib for the first time under approved indications at medical institutions. The study will monitor outcomes related to the treatment's impact on psoriasis symptoms and any adverse effects experienced by the participants. The findings will contribute to post-marketing surveillance data for this medication.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with plaque psoriasis who are starting treatment with deucravacitinib for the first time.
Not a fit: Patients receiving deucravacitinib for off-label indications will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and effectiveness of deucravacitinib for patients with psoriasis.
How similar studies have performed: Other studies assessing the safety and effectiveness of similar treatments for psoriasis have shown promising results, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS Exclusion Criteria: * Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.
Where this trial is running
Tosima-ku, Tokyo
- EP Pharmaline — Tosima-ku, Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.